Similar articles

• Heparin-induced thrombocytopenia and antithrombotic therapy.

  Boon DM, Michiels JJ, Stibbe J, van Vliet HH, Kappers-Klunne MC. Boon DM, et al. Lancet. 1994 Nov 5;344(8932):1296. doi: 10.1016/s0140-6736(94)90781-1. Lancet. 1994. PMID: 7526097 No abstract available.
• Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

  Lubenow N, Greinacher A. Lubenow N, et al. J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:47-57. doi: 10.1023/a:1027333320023. J Thromb Thrombolysis. 2000. PMID: 11155194 Review. No abstract available.
• [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].

  [No authors listed] [No authors listed] Anaesthesist. 1998 Nov;47(11 Suppl Massnahmen):1-4. Anaesthesist. 1998. PMID: 9884734 German. No abstract available.
• Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes.

  Rice L, Nguyen PH, Vann AR. Rice L, et al. Postgrad Med. 2002 Sep;112(3):85-9. doi: 10.3810/pgm.2002.09.1307. Postgrad Med. 2002. PMID: 12360660
• Heparin-induced thrombocytopenia: pathophysiology and management.

  Mureebe L, Silver D. Mureebe L, et al. Vasc Endovascular Surg. 2002 May-Jun;36(3):163-70. doi: 10.1177/153857440203600302. Vasc Endovascular Surg. 2002. PMID: 12075381 Review.